Moderna shares slide as traders digest recent EU vaccine clearance and refocus on funding/earnings overhangs

Moderna, Inc. (MRNA) is down 4.0% today. Here is some analysis on what might have caused this price movement.

Analysis: The move looks most consistent with a post-news pullback after recent Europe-related regulatory wins, with attention shifting back to near-term cash burn and upcoming earnings. Investors may also be weighing the financial implications of Moderna advancing certain influenza programs despite reduced U.S. government support, which can raise uncertainty around funding and timelines.

Details:

This week, Moderna announced that the European Commission granted marketing authorization for its combined influenza/COVID-19 vaccine (mRNA-1083) for adults ages 50+, a headline that can create a short-term “buy the rumor, sell the news” dynamic after an initial pop.

European regulatory materials around the combo product outline the intended population and authorization pathway, reinforcing that commercialization still depends on country-by-country access and rollout mechanics.

Moderna also said it is moving forward with a bird flu (H5) vaccine trial even after losing substantial U.S. government funding support, which can be read as strategically positive but financially dilutive near term.

With Moderna expected to report results soon, some investors may be de-risking ahead of the print given ongoing debate around the pace of revenue replacement beyond COVID-related products.

Sources:

BioSpace (Access Newswire), European Medicines Agency, BioPharma Dive

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$MRNA Insider Trading Activity

$MRNA insiders have traded $MRNA stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.

Here’s a breakdown of recent trading of $MRNA stock by insiders over the last 6 months:

STEPHEN HOGE (President) sold 160,009 shares for an estimated $7,814,839
SHANNON THYME KLINGER (Chief Legal Officer) sold 13,885 shares for an estimated $726,046
NOUBAR AFEYAN sold 23,853 shares for an estimated $703,305
ABBAS HUSSAIN sold 504 shares for an estimated $13,910

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.

EARLY ACCESS

Receive MRNA Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$MRNA Hedge Fund Activity

We have seen 286 institutional investors add shares of $MRNA stock to their portfolio, and 318 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC added 15,741,014 shares (+127.9%) to their portfolio in Q4 2025, for an estimated $464,202,502
CAPITAL WORLD INVESTORS added 12,828,040 shares (+inf%) to their portfolio in Q4 2025, for an estimated $378,298,899
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 6,254,709 shares (-79.7%) from their portfolio in Q4 2025, for an estimated $184,451,368
ALYESKA INVESTMENT GROUP, L.P. added 3,228,531 shares (+inf%) to their portfolio in Q4 2025, for an estimated $95,209,379
BNP PARIBAS FINANCIAL MARKETS added 3,058,933 shares (+279.7%) to their portfolio in Q4 2025, for an estimated $90,207,934
BLACKROCK, INC. added 2,977,816 shares (+10.1%) to their portfolio in Q4 2025, for an estimated $87,815,793
CITADEL ADVISORS LLC removed 1,408,601 shares (-70.9%) from their portfolio in Q4 2025, for an estimated $41,539,643

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

$MRNA Analyst Ratings

Wall Street analysts have issued reports on $MRNA in the last several months. We have seen 1 firms issue buy ratings on the stock, and 2 firms issue sell ratings.

Here are some recent analyst ratings:

Piper Sandler issued a "Overweight" rating on 02/23/2026
Leerink Partners issued a "Underperform" rating on 11/21/2025
B of A Securities issued a "Underperform" rating on 11/10/2025

To track analyst ratings and price targets for $MRNA, check out Quiver Quantitative's $MRNA forecast page.

$MRNA Price Targets

Multiple analysts have issued price targets for $MRNA recently. We have seen 11 analysts offer price targets for $MRNA in the last 6 months, with a median target of $30.0.

Here are some recent targets:

Eliana Merle from Barclays set a target price of $48.0 on 04/02/2026
Edward Tenthoff from Piper Sandler set a target price of $69.0 on 02/23/2026
Cory Kasimov from Evercore ISI Group set a target price of $35.0 on 02/17/2026
Salveen Richter from Goldman Sachs set a target price of $41.0 on 02/17/2026
Luca Issi from RBC Capital set a target price of $30.0 on 02/17/2026
Eliana Merle from UBS set a target price of $34.0 on 01/07/2026
Andrew Tsai from Jefferies set a target price of $30.0 on 12/12/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.